1530 Stock Overview
An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
3SBio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.39 |
| 52 Week High | HK$7.69 |
| 52 Week Low | HK$4.91 |
| Beta | 0.68 |
| 11 Month Change | 26.54% |
| 3 Month Change | 17.30% |
| 1 Year Change | 12.82% |
| 33 Year Change | 0.54% |
| 5 Year Change | -45.10% |
| Change since IPO | -5.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1530 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 15.3% | 15.8% | 9.6% |
| 1Y | 12.8% | 12.4% | 27.2% |
Return vs Industry: 1530 matched the Hong Kong Biotechs industry which returned 12.4% over the past year.
Return vs Market: 1530 underperformed the Hong Kong Market which returned 27.2% over the past year.
Price Volatility
| 1530 volatility | |
|---|---|
| 1530 Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in HK Market | 17.4% |
| 10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 1530 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1530's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 5,607 | Jing Lou | www.3sbio.com |
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium.
3SBio Inc. Fundamentals Summary
| 1530 fundamental statistics | |
|---|---|
| Market cap | HK$17.41b |
| Earnings (TTM) | HK$1.83b |
| Revenue (TTM) | HK$9.27b |
9.5x
P/E Ratio1.9x
P/S RatioIs 1530 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1530 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.42b |
| Cost of Revenue | CN¥1.18b |
| Gross Profit | CN¥7.24b |
| Other Expenses | CN¥5.58b |
| Earnings | CN¥1.66b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.70 |
| Gross Margin | 85.94% |
| Net Profit Margin | 19.69% |
| Debt/Equity Ratio | 24.7% |
How did 1530 perform over the long term?
See historical performance and comparison